Document Type : Original Article


Smt. Sarojini Ramulamma College of Pharmacy, Seshadrinagar, Mahabubnagar, Telangana 509001, India


The objective of the study is to compare and evaluate the efficacy of atorvastatin (group – A) versus rosuvastatin (group – B) on baseline parameters like lipid profile tests and to assess the risk of metabolic syndrome using a Mets calculator. A total of 100 patients were enclosed in the present study who met the inclusion criteria. They were divided into two groups based on their treatment plan Group A includes 24 males and 26 females while Group B includes 23 males and 27 females. The mean differences before treatment for group A and group B are as follows, HDL (31.52±0.35 and 28.34±0.480), LDL (161.4±1.09 and 163.16±0.94), Total cholesterol (252.82±1.09 and 255.56±1.26) and Triglycerides (214.2±0.86 and 215.98±0.62), VLDL (35.98±0.56 and 36.12±0.43). The mean differences after treatment for group A and group B are as follows HDL (39.92±0.46 and 42.04±0.30), LDL (144.96±0.68 and 138.34±0.73), Total cholesterol (181.48±1.98 vs 174.32±2.08), Triglycerides (185.94±1.22 vs 181.74±1.77), VLDL (27.14±0.21 and 24.72±0.27). Group B (P=0.001) exhibited a significantly greater reduction in cholesterol levels as compared to Group A (P = 0.002). The reductions in LDL, VLDL, Total Cholesterol, and Triglycerides along with increased HDL levels were found to be significantly more in the Rosuvastatin group. In this study, we observed that patients on Rosuvastatin exhibited better control over lipid profile when compared to patients who are on Atorvastatin. Since, this study was conducted on a smaller number of patients, to make consecutive remarks about the superiority of either of the treatment regimen; further analysis of clinical trials is required for appropriate selection of the best statin therapy.  

Graphical Abstract

Comparative study on the efficacy of statin therapy in lowering cholesterol and assessing the risk of metabolic syndrome in patients under statins therapy


Main Subjects

Selected author of this article by journal

Dr. Paspula Soumya
Sarojini Ramulamma College of Pharmacy

Open Access

This article is licensed under a CC BY License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit:


Publisher’s Note

CMBR journal remains neutral with regard to jurisdictional claims in published maps and institutional afflictions.


Letters to Editor

Given that CMBR Journal's policy in accepting articles will be strict and will do its best to ensure that in addition to having the highest quality published articles, the published articles should have the least similarity (maximum 15%). Also, all the figures and tables in the article must be original and the copyright permission of images must be prepared by authors. However, some articles may have flaws and have passed the journal filter, which dear authors may find fault with. Therefore, the editor of the journal asks the authors, if they see an error in the published articles of the journal, to email the article information along with the documents to the journal office.

CMBR Journal welcomes letters to the editor ([email protected], [email protected]) for the post-publication discussions and corrections which allows debate post publication on its site, through the Letters to Editor. Critical letters can be sent to the journal editor as soon as the article is online. Following points are to be considering before sending the letters (comments) to the editor.

[1] Letters that include statements of statistics, facts, research, or theories should include appropriate references, although more than three are discouraged.

[2] Letters that are personal attacks on an author rather than thoughtful criticism of the author’s ideas will not be considered for publication.

[3] There is no limit to the number of words in a letter.

[4] Letter writers should include a statement at the beginning of the letter stating that it is being submitted either for publication or not.

[5] Anonymous letters will not be considered.

[6] Letter writers must include Name, Email Address, Affiliation, mobile phone number, and Comments.

[7] Letters will be answered as soon as possible.

  1. Niwa K (2021) Metabolic syndrome and coronary artery disease in adults with congenital heart disease. Cardiovascular diagnosis and therapy 11 (2): 563-576. doi:
  2. Lin T-Y, Chien K-L, Chiu Y-H, Chuang P-C, Yen M-F, Chen H-H (2021) Dynamics of detailed components of metabolic syndrome associated with the risk of cardiovascular disease and death. Scientific Reports 11 (1): 3677. doi:
  3. Bhalwar R (2020) Metabolic syndrome: The Indian public health perspective. Medical Journal Armed Forces India 76 (1): 8-16. doi:
  4. Yoon SJ, Kim SK, Lee NY, Choi YR, Kim HS, Gupta H, Youn GS, Sung H, Shin MJ, Suk KT (2021) Effect of Korean Red Ginseng on metabolic syndrome. Journal of Ginseng Research 45 (3): 380-389. doi:
  5. Na Z, Jiang H, Meng Y, Song J, Feng D, Fang Y, Shi B, Li D (2022) Association of galactose and insulin resistance in polycystic ovary syndrome: A case-control study. eClinicalMedicine 47): 101379. doi:
  6. Herrett E, Strongman H, Gadd S, Tomlinson L, Nitsch D, Bhaskaran K, Williamson E, van Staa T, Sofat R, Timmis A, Wells S, Smeeth L, Jackson R (2022) The importance of blood pressure thresholds versus predicted cardiovascular risk on subsequent rates of cardiovascular disease: a cohort study in English primary care. The Lancet Healthy Longevity 3 (1): e22-e30. doi:
  7. Handelsman Y, Jellinger PS, Guerin CK, Bloomgarden ZT, Brinton EA, Budoff MJ, Davidson MH, Einhorn D, Fazio S, Fonseca VA, Garber AJ, Grunberger G, Krauss RM, Mechanick JI, Rosenblit PD, Smith DA, Wyne KL (2020) Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm – 2020 Executive Summary. Endocrine Practice 26 (10): 1196-1224. doi:
  8. Alberti KGMM, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic medicine 15 (7): 539-553. doi:;2-S
  9. Music M, Dervisevic A, Pepic E, Lepara O, Fajkic A, Ascic-Buturovic B, Tuna E (2015) Metabolic Syndrome and Serum Liver Enzymes Level at Patients with Type 2 Diabetes Mellitus. Medical archives (Sarajevo, Bosnia and Herzegovina) 69 (4): 251-255. doi:
  10. Kachur S, Morera R, De Schutter A, Lavie CJ (2018) Cardiovascular Risk in Patients with Prehypertension and the Metabolic Syndrome. Current Hypertension Reports 20 (2): 15. doi:
  11. Ansarimoghaddam A, Adineh HA, Zareban I, Iranpour S, HosseinZadeh A, Kh F (2018) Prevalence of metabolic syndrome in Middle-East countries: Meta-analysis of cross-sectional studies. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 12 (2): 195-201. doi:
  12. Zhao Y, Evans MA, Allison MA, Bertoni AG, Budoff MJ, Criqui MH, Malik S, Ouyang P, Polak JF, Wong ND (2019) Multisite atherosclerosis in subjects with metabolic syndrome and diabetes and relation to cardiovascular events: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 282): 202-209. doi:
  13. Haswell C, Ali A, Page R, Hurst R, Rutherfurd-Markwick K (2021) Potential of Beetroot and Blackcurrant Compounds to Improve Metabolic Syndrome Risk Factors. Metabolites 11 (6): 338. doi:
  14. Alshammary AF, Alharbi KK, Alshehri NJ, Vennu V, Ali Khan I (2021) Metabolic syndrome and coronary artery disease risk: a meta-analysis of observational studies. International Journal of Environmental Research and Public Health 18 (4): 1773. doi:
  15. Werida R, Khairat I, Khedr NF (2021) Effect of atorvastatin versus rosuvastatin on inflammatory biomarkers and LV function in type 2 diabetic patients with dyslipidemia. Biomedicine & Pharmacotherapy 135): 111179. doi:
  16. Kummen M, Solberg OG, Storm-Larsen C, Holm K, Ragnarsson A, Trøseid M, Vestad B, Skårdal R, Yndestad A, Ueland T, Svardal A, Berge RK, Seljeflot I, Gullestad L, Karlsen TH, Aaberge L, Aukrust P, Hov JR (2020) Rosuvastatin alters the genetic composition of the human gut microbiome. Scientific Reports 10 (1): 5397. doi:
  17. Fahmy MIM, Sayed RH, El-Yamany MF, El-Naggar R, A. Eliwa H (2022) Rosuvastatin and co-enzyme Q10 improve high-fat and high-fructose diet-induced metabolic syndrome in rats via ameliorating inflammatory and oxidative burden. Biomedicine & Pharmacotherapy 153): 113526. doi:
  18. Al-Sabti H, Al-Hinai AT, Al-Zakwani I, Al-Hashmi K, Al Mahmeed W, Arafah M, Shehab A, Al Tamimi O, Al Awadhi M, Al Herz S, Al Anazi F, Al Nemer K, Metwally O, Alkhadra A, Fakhry M, Elghetany H, Medani AR, Yusufali AH, Al Jassim O, Al Hallaq O, Baslaib F, Amin H, Al-Waili K, Al-Rasadi K (2022) The Achievement of Non-high-density Lipoprotein Cholesterol Target in Patients with Very High Atherosclerotic Cardiovascular Disease Risk Stratified by Triglyceride Levels Despite Statin-controlled Low-density Lipoprotein Cholesterol. Oman medical journal 37 (2): e367. doi:
  19. Gu A, Kamat S, Argulian E (2018) Trends and disparities in statin use and low-density lipoprotein cholesterol levels among US patients with diabetes, 1999–2014. Diabetes Research and Clinical Practice 139): 1-10. doi:
  20. Santos HO, Earnest CP, Tinsley GM, Izidoro LFM, Macedo RCO (2020) Small dense low-density lipoprotein-cholesterol (sdLDL-C): Analysis, effects on cardiovascular endpoints and dietary strategies. Progress in Cardiovascular Diseases 63 (4): 503-509. doi:
  21. Chilbert MR, VanDuyn D, Salah S, Clark CM, Ma Q (2022) Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights. Drug Des Devel Ther 16): 2177-2186. doi:
  22. Rizos CV, Skoumas I, Rallidis L, Skalidis E, Tziomalos K, Garoufi A, Anagnostis P, Sfikas G, Kotsis V, Doumas M, Kolovou G, Lambadiari V, Dima I, Kiouri E, Zacharis E, Agapakis D, Attilakos A, Antza C, Vlachopoulos C, Liberopoulos EN (2021) LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments. International Journal of Cardiology 345): 119-124. doi:
  23. Tabrizi R, Tamtaji OR, Mirhosseini N, Lankarani KB, Akbari M, Dadgostar E, Borhani-Haghighi A, Peymani P, Ahmadizar F, Asemi Z (2019) The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. Pharmacological Research 141): 85-103. doi: